Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36: a Phase 1 Study

Trial Profile

Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36: a Phase 1 Study

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Oct 2015

At a glance

  • Drugs Glucagon-like peptide-1 (Primary) ; Peptide YY 3-36 (Primary)
  • Indications Obesity
  • Focus Pharmacodynamics
  • Most Recent Events

    • 24 Sep 2010 Salcaprozate-sodium added as descriptor, as reported in an Emisphere Technologies media release.
    • 24 Sep 2010 Results published in the American Journal of Clinical Nutrition, 18 August 2010, according to an Emisphere Technologies media release.
    • 27 May 2009 Results have been reported in a media release from Emisphere Technologies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top